Format
Sort by
Items per page

Send to

Choose Destination

Best matches for EGFR nanobody:

Search results

Items: 1 to 20 of 44

1.

Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach.

Kooijmans SAA, Gitz-Francois JJJM, Schiffelers RM, Vader P.

Nanoscale. 2018 Feb 1;10(5):2413-2426. doi: 10.1039/c7nr06966a.

2.

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017.

PMID:
29296532
3.

The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.

van Lith SAM, van den Brand D, Wallbrecher R, Wübbeke L, van Duijnhoven SMJ, Mäkinen PI, Hoogstad-van Evert JS, Massuger L, Ylä-Herttuala S, Brock R, Leenders WPJ.

Eur J Pharm Biopharm. 2018 Mar;124:63-72. doi: 10.1016/j.ejpb.2017.12.009. Epub 2017 Dec 20.

4.

A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.

Xu L, Song X, Jia L.

Biotechnol Appl Biochem. 2017 Nov;64(6):895-901. doi: 10.1002/bab.1544. Epub 2017 Aug 29.

PMID:
28853185
5.

Quantum-Dot-Based Theranostic Micelles Conjugated with an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy.

Wang Y, Wang Y, Chen G, Li Y, Xu W, Gong S.

ACS Appl Mater Interfaces. 2017 Sep 13;9(36):30297-30305. doi: 10.1021/acsami.7b05654. Epub 2017 Aug 28.

PMID:
28845963
6.

Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors.

Zhu Y, Bassoff N, Reinshagen C, Bhere D, Nowicki MO, Lawler SE, Roux J, Shah K.

Sci Rep. 2017 Jun 1;7(1):2602. doi: 10.1038/s41598-017-02483-9.

7.

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.

Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, Ludwig F, Ziller-Walter P, Kegler A, Gärtner S, Schmitz M, Ehninger A, Cartellieri M, Ehninger G, Pietzsch HJ, Pietzsch J, Steinbach J, Bachmann M.

Oncoimmunology. 2017 Feb 6;6(4):e1287246. doi: 10.1080/2162402X.2017.1287246. eCollection 2017.

8.

Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro.

Deng C, Xiong J, Gu X, Chen X, Wu S, Wang Z, Wang D, Tu J, Xie J.

Oncotarget. 2017 Jun 13;8(24):38568-38580. doi: 10.18632/oncotarget.16930.

9.

Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.

Farasat A, Rahbarizadeh F, Hosseinzadeh G, Sajjadi S, Kamali M, Keihan AH.

J Biomol Struct Dyn. 2017 Jun;35(8):1710-1728. doi: 10.1080/07391102.2016.1192065. Epub 2016 Oct 3.

PMID:
27691399
10.

<sup>99m</sup> Tc-anti-epidermal growth factor receptor nanobody for tumor imaging.

Piramoon M, Hosseinimehr SJ, Omidfar K, Noaparast Z, Abedi SM.

Chem Biol Drug Des. 2017 Apr;89(4):498-504. doi: 10.1111/cbdd.12871. Epub 2016 Nov 5.

PMID:
27650045
11.

Anti-EGFR-iRGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency.

Bian X, Wu P, Sha H, Qian H, Wang Q, Cheng L, Yang Y, Yang M, Liu B.

Onco Targets Ther. 2016 May 27;9:3153-62. doi: 10.2147/OTT.S100678. eCollection 2016.

12.

EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.

van Driel PB, Boonstra MC, Slooter MD, Heukers R, Stammes MA, Snoeks TJ, de Bruijn HS, van Diest PJ, Vahrmeijer AL, van Bergen En Henegouwen PM, van de Velde CJ, Löwik CW, Robinson DJ, Oliveira S.

J Control Release. 2016 May 10;229:93-105. doi: 10.1016/j.jconrel.2016.03.014. Epub 2016 Mar 15.

13.

Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting.

Kooijmans SA, Aleza CG, Roffler SR, van Solinge WW, Vader P, Schiffelers RM.

J Extracell Vesicles. 2016 Mar 14;5:31053. doi: 10.3402/jev.v5.31053. eCollection 2016.

14.

In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the Epidermal Growth Factor Receptor.

Krüwel T, Nevoltris D, Bode J, Dullin C, Baty D, Chames P, Alves F.

Sci Rep. 2016 Feb 25;6:21834. doi: 10.1038/srep21834.

15.

PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time.

Kooijmans SAA, Fliervoet LAL, van der Meel R, Fens MHAM, Heijnen HFG, van Bergen En Henegouwen PMP, Vader P, Schiffelers RM.

J Control Release. 2016 Feb 28;224:77-85. doi: 10.1016/j.jconrel.2016.01.009. Epub 2016 Jan 7.

PMID:
26773767
16.

Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.

Ding L, Tian C, Feng S, Fida G, Zhang C, Ma Y, Ai G, Achilefu S, Gu Y.

Theranostics. 2015 Jan 21;5(4):378-98. doi: 10.7150/thno.10084. eCollection 2015.

17.

Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.

Nevoltris D, Lombard B, Dupuis E, Mathis G, Chames P, Baty D.

ACS Nano. 2015 Feb 24;9(2):1388-99. doi: 10.1021/nn505752u. Epub 2015 Jan 26.

PMID:
25603171
18.

Capillary electrophoresis-based assessment of nanobody affinity and purity.

Haselberg R, Oliveira S, van der Meel R, Somsen GW, de Jong GJ.

Anal Chim Acta. 2014 Mar 25;818:1-6. doi: 10.1016/j.aca.2014.01.048. Epub 2014 Feb 4.

PMID:
24626396
19.

Nanobody-photosensitizer conjugates for targeted photodynamic therapy.

Heukers R, van Bergen en Henegouwen PM, Oliveira S.

Nanomedicine. 2014 Oct;10(7):1441-51. doi: 10.1016/j.nano.2013.12.007. Epub 2014 Jan 3.

PMID:
24394212
20.

Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody.

van Driel PB, van der Vorst JR, Verbeek FP, Oliveira S, Snoeks TJ, Keereweer S, Chan B, Boonstra MC, Frangioni JV, van Bergen en Henegouwen PM, Vahrmeijer AL, Lowik CW.

Int J Cancer. 2014 Jun 1;134(11):2663-73. doi: 10.1002/ijc.28601. Epub 2013 Dec 12.

Supplemental Content

Loading ...
Support Center